ArticleMolecular cancer therapeutics2025

OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.

Wan-Fen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.